PUBLISHED ARTICLES:
1.
Fraser AG,
Henley JW, Ellis-Pegler RB, Benjamin CS, Childs WJ, Harvey VJ. The acquired
immunodeficiency syndrome in Auckland
in 1985. New Zealand Medical Journal 1986:99; 485-488
2.
Fraser AG,
Croxson MS, Ellis-Pegler RB.
Hypercalcaemia and elevated 1,25 dihydroxy-vitamin D3 levels in a patient with multibacillary
leprosy and type 1 leprosy reaction. New
Zealand Medical Journal. 1987:100; 86.
3.
Fraser
AG, Croxson MS, Espiner EA, Synek B.
Adrenocortical carcinoma presenting as primary aldosteronism in a young
man. Australian
New Zealand
Journal of Medicine 1987:17; 60-62.
4.
Ellis-Pegler RB,
Beeching NJ, Eales M, Fraser AG, Wells
AU. Fansimef is effective treatment for imported malaria in New Zealand. Australian New Zealand Journal of Medicine
1988:18; 733-734.
5.
Browett PJ, Fraser AG, Varcoe AR, Ellis-Pegler
RB. Disseminated tuberculosis complicated by hemophagocytic
syndrome. Australian New
Zealand Journal of Medicine 1988:18;
79-80.
6.
Fraser AG.
Medicine in rural Kenya
- a personal perspective. New
Zealand Medical Journal 1989:102; 15-16.
7.
Fraser AG,
Hamilton I. Endoscopic palliation of malignant obstructive jaundice. New Zealand Medical Journal 1989:102; 155-157.
8.
Fraser AG, Parr DH, Ellis-Pegler RB. The spectrum of systemic
candidiasis at Auckland
Hospital. New Zealand Medical Journal 1990:103; 505-507.
9.
Fraser AG, Arthur J, Hamilton I.
Intestinal psuedo-obstruction secondary to gastrointestinal amyloidosis
responsive to treatment with cisapride. Digestive Diseases and Sciences 1991:36;
532-535.
10.
Fraser AG, Prewett EJ, Sawyer AM, Rosalki SB, Pounder RE. The effect
of ranitidine, cimetidine of famotidine on low-dose post-prandial alcohol
absorption. Alimentary Pharmacology and Therapeutics 1991;5:263-272.
11.
Prewett EJ,
Nwokolo CU, Hudson M, Sawyerr AM, Fraser
AG, Pounder RE. The effect of GR
122311X, a bismuth compound with H2-antagonist activity, on 24-hour acidity. Alimentary Pharmacology Therapeutics
1991;5: 481-490.
12.
Charkravanty BK, Fraser
AG, Hamilton I, Lane M. A randomised, blinded study in colonic lavage for
colonoscopy. Australian and New Zealand Journal of Medicine 1991;21: 769-771.
13.
Fraser AG, Debnam ES, Dhillon AP, Pounder
RE. Gastric epithelial cell proliferation after dosing with
anti-secretory drugs: the effect of variation in the strain of rat. European
Journal of Gastroenterolgy and Hepatology 1992; 4:651-656
14.
Fraser AG,
Nicholson GI. Duodenal perforation in
primary systemic amyloidosis. Gut 1992;
33: 997-9.
15.
Fraser AG,
Prewett EJ, Hudson M, Sawyerr AM, Rosalki SB, Pounder RE. Ranitidine has no
effect on post-prandial absorption of alcohol (0.6g/kg) after an evening
meal. European Journal Gastroenterology and Hepatology 1992;4: 43-48.
16.
Fraser AG, Debnam ES, Dhillon AP, Pounder RE. Gastric epithelial cell proliferation and histological
damage after dosing with hypertonic saline: the effect of variation in the
strain of rat. International Journal Experimental
Pathology 1992; 73: 241-250
17.
Fraser AG, Hudson M, Sawyerr AM, Rosalki SB,
Pounder RE. The effect of ranitidine on the
post-prandial absorption of a low dose of alcohol. Alimentary Pharmacology Therapeutics 1992; 6: 267-271
18.
Fraser AG,
Pounder RE. H2-antagonists and alcohol. Reply. Aliment Pharmacol Therapeutics 1991;5:
668-670.
19.
Fraser AG,
Prewett EJ, Pounder RE, Samloff IM. Twenty-four hour hyperpepsinogenaemia in Helicobacter pylori-positive subjects is
abolished by eradication of the infection. Alimentary
Pharmacology Therapeutics 1992, 6:483-394
20.
Pounder
RE, Fraser AG. Safety concerns related to the treatment of
peptic ulceration. Current opinion in
Gastroenterology 1992;7: 894-899.
21.
Prewett EJ, Luk YW, Fraser
AG, Lam WM, Pounder RE. Comparison of one-day oral dosing with three bismuth
compounds for the suppression of Helicobacter
pylori assessed by the 13C-urea breath test. Alimentary Pharmacology and Therapeutics 1992;6: 97-102.
22.
Fraser AG,
Hudson M, Sawyer AM, Smith M, Rosalki SB, Pounder RE. Ranitidine, cimetidine,
famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken
after an evening meal. Alimentary Pharmacology and Therapeutics
1992;6: 693-700
23.
Fraser AG,
Nicholson GI. Long-term follow-up of
dilatation treatment of oesophageal strictures. J Gastroenterology and Hepatology 1992, 7: 520-523
24. Fraser AG, White C, Nicholson G.
Antral vascular
ectasia. N.Z.Med J 1992; 105: 338-9.
25.
Fraser AG, Bickley J, Owen R, Pounder RE. DNA
fingerprints of Helicobacter pylori
before and after treatment with omeprazole.
J Clinical Pathology 1992; 45:
1062-1065.
26.
Fraser AG, Lam
WM, Luk YW, Sawyerr AM, Hudson M, Smith M, Pounder RE. The effect of ranitidine bismuth citrate on
post-prandial plasma gastrin and plasma pepsinogens. Gut 1993;34: 338-342
27.
Fraser AG,
Sawyerr AM, Hudson
M, Smith M, Pounder RE. The effect of ranitidine on post-breakfast alcohol
absorption. American Journal of
Gastroenterology 1993;88: 217-221
28.
Fraser AG, Pounder RE, Burroughs AK. Gastric secretion and peptic ulcer in cirrhosis. Journal of Hepatology 1993; 19: 171-182
29.
Bickley J, Owen RJ, Fraser
AG, Pounder RE. Evaluation of the polymerase chain reaction for detecting
the urease gene of Helicobacter pylori
in gastric biopsies and dental plaque. Journal of Medical Microbiology 1993;
39: 338-344.
30.
Fraser AG,
Sawyerr AM, Hudson
M, Smith M, Pounder RE. Effects of
ranitidine 150 mg qds on 24-hour intragastric acidity and 24-h plasma gastrin
concentration. Digestive Diseases and Sciences 1994; 39: 91-96.
31.
Owen
RJ, Bickley J, Hurtado A, Fraser AG
and Pounder RE. Use of rRNA gene
profiling and polymerase chain reaction-based restriction length polymorphism
analysis of urease genes to monitor Helicobacter
pylori infecting patients on triple therapy. Journal
of Clinical Microbiology; 1994; 32: 1203-1210.
32.
Fraser AG, Sim R, Sankey EA, Dhillon AP, Pounder
RE. Effect of eradication of
Helicobacter pylori on gastric epithelial cell proliferation. Aliment Pharmacol Therap 1994; 8:
167-173.
33.
Fraser AG, Lewin JF, Pounder RE. Gastric
persorption of bismuth from ranitidine bismuth citrate. Aliment
Pharmacol Therap 1995:9:447-450.
34.
Fraser AG,
Rosalki SB, Gamble GG, Pounder RE.
Inter-individual and intra-individual variabililty of ethanol
concentration-time profiles: comparison of ethanol ingestion before or after an
evening meal. Br J Clin Pharmacol 1995;40:387-392.
35.
Fraser AG, Ali
MR, McCullough S, Haystead A. Diagnostic
tests for Helicobacter pylori - can
they help select patients for endoscopy?
NZ Med J 1996; 109: 95-8.
36.
Fraser AG,
Moore L, Ali MR, Hollis B, Little SV. An
audit of low dose triple therapy for eradication of Helicobacter pylori. NZ Med J 1996; 109; 290-2
37.
Fraser AG, Sawyerr AM, Hudson M, Smith MS, Pounder RE. Morning
versus evening dosing of lansoprazole 30mg daily on 24‑hour intragastric
acidity in healthy subjects. Aliment
Pharmacol Therap 1996; 10: 523-527.
38.
Scragg
RK, Fraser A, Metcalf PA. Helicobacter
pylori and cardiovascular risk factors in a multicultural workforce. J Epid
Comm Health 1996:50:578-79.
39.
O’Morian
C, Dettmer A, Rambow A, von Fritsch E, Fraser
AG. Double-blind multinational,
multicentre, placebo-controlled evaluation of clarithromycin and omeprazole for
Helicobacter pylori associated
duodenal ulcer. Helicobacter 1996; 1:130-137.
40.
Fraser AG,
Scragg R, Metcalf P, McCullough S, Yeates NJ.
Prevalence of Helicobacter pylori
in different ethnic groups in New
Zealand children and adults. Aust NZ J Med 1996; 26:646-51 (with
editorial).
41.
Fraser AG,
Moore L, Berry
S, Arroll B. Eradication treatment for Helicobacter pylori in general practice. NZ Med
J 1996; 109:422-4.
42.
Berry
S, Arroll B, Fraser AG, Weller D.
Screening for colorectal cancer: a
survey of New Zealand
general practitioners. NZ Med J 1996; 109:447-9.
43.
Perez-Perez
GI, Bhat N, Gaensbauer J, Fraser AG,
Taylor DN, Kuipers EJ, Zhang L, You WC, Blaser MJ. Country-specific constancy by age in CagA+
proportion of Helicobacter pylori infections.
Int J of Cancer 1997; 72:
453-56.
44.
Schmid J, Fraser
AG, Hollis B, O’Toole P. Ethnic tropism of DNA fingerprints of Helicobacter pylori. Infection and Immunity 1997; 65:
3708-12.
45.
Fraser AG, Peng S-L, Jass JR. Intestinal
metaplasia subtypes and Helicobacter
pylori infection - a comparison of ethnic groups in New Zealand.
J Gastro Hepatol 1998; 13: 560-565.
46.
Fraser AG, McIntosh C, Berry
S, Moore
L. Can the urea breath test for H.pylori replace endoscopy for the
assessment of dyspepsia in primary care?
N Z J Med 1998; 111; 11-4.
47.
Fraser AG, Schreuder V, Chua L, Moore L. Follow-up
after successful eradication of H.pylori
- symptoms and re-infection. J Gastro Hepatol 1998; 13: 555-59.
48.
Perssons
S, Lane MR, Fraser AG. Long-term follow-up of the management of
oesophageal strictures at Auckland
Hospital 1990-94. NZ Med
J 1999; 112: 28-29.
49.
Garrigan
K, McIntosh C, Fraser AG. Bleeding peptic ulcers: audit of eradication
for H.pylori. NZ Med J 1999; 112: 178-180.
50.
Fraser AG, Woollard GA. Gastric juice ascorbic acid is related to
Helicobacter pylori infection bit not ethnicity. J
Gastro Hepatol 1999; 14: 1070-73.
51.
Fraser AG, Moore L, Hackett M, Hollis B. H.pylori
treatment and antibiotic susceptibility: results of a five-year audit. Aust
NZ J Med 1999; 29:512-517.
52.
Fraser AG, Morton
RP, Gillebrand J. Presumed
laryngo-pharyngeal reflux; investigate or treat. J Otolaryngology 2000; 114: 441-47.
53.
Fraser AG,
Orchard TR, Jewell DP. The efficacy of
azathioprine for the treatment of inflammatory bowel disease: a 30 year
review. Gut 2002; 50: 485-489.
54.
Fraser AG,
Morton D, McGovern D, Travis S, Jewell DP.
The efficacy of methotrexate for maintaining remission in inflammatory
bowel disease. Aliment Pharmacol Therap 2002; 16: 693-697.
55.
Fraser AG,
Orchard TR, Robinson EM, Jewell DP.
Long-term risk of malignancy after treatment of inflammatory bowel
disease with azathioprine. Aliment Pharmacol Therap 2002; 16:
1225-1232.
56. Fraser AG, Warren BF, Chandrapala R, Jewell DP. Microscopic
colitis: a clinical and pathological review.
Scand J Gastroenterol 2002; 11: 1241-45.
57. Fraser
AG, Scragg RK,
Cox B, Jackson RT. Helicobacter
pylori, Chlamydia pneumoniae and myocardial infarction. Int Med J 2003; 33: 267-272.
58.
Fraser AG, Williamson S, Lane MR, Hollis B. Nurse-led dyspepsia clinic using the urea
breath test for H.pylori. NZ Med J 2003;
116: 479-83.
59.
Fraser AG. Helicobacter pylori: a historical
perspective 1983-2003. NZ Med J; 2004; 117: 1194
60.
Fraser AG, Kandiel A, Korelitz BI,
Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease
patients treated with azathioprine and 6-mercaptopurine Gut 2005; 54, 1121-1125
61.
Leung
E, Hong J, Fraser AG, Merriman TR, Vishnu
P, Abbott WGH, Krissansen GW. Polymorphisms of
CARD15/NOD2 and CD14 genes in New Zealand Crohn's disease patients. Immunology
and Cell Biology 2005; 83: 498-503.
62.
Leung
E, Hong J, Fraser AG, Merriman TR, Vishnu
P, Abbott WGH, Krissansen GW Peroxisome proliferator-activated receptor-g gene
polymorphisms and Crohn's disease. Int J Colorectal Dis 2007; 22:453-4.
63.
Leung E, Hong J, Fraser
AG, et al. Polymorphisms in the organic cation transporter genes
SLC22A4 and SLC22A5 and Crohn’s diseas in a New Zealand caucasian cohort. Immunoly and Cell Biology 2006; 84: 233-6.
64.
Leung E, Hong J, Fraser
AG, Merriman T, Krissansen G. PPAR-gamma and Crohn’s disease. Gastroenterology 2005; 128:351-60. Author reply Gastroenterology 2006;
130:2249-50.
65.
Leung
E, Hong J, Fraser AG, Krissansen
GW. Spicing of NOD2 (CARD15) RNA transcripts. Molecular Immunology 2007; 8:995-6.
66. Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. Colony-stimulating factor-1 receptor gene
polymorphisms. Int J Colorect Dis 2007;
8: 995-6.
67. Leung E. Hong J. Fraser AG. Merriman TR. Vishnu P. Krissansen GW. Polymorphisms in the organic
cation transporter genes SLC22A4 and SLC22A5 and Crohn's disease in a New
Zealand Caucasian cohort. Immunology & Cell Biology 2006; 84:233-6.
68. Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. TLR2, TLR4 and TLR9 polymorphisms
and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol
2007: 22: 1760-1766.
69. Hong J, Leung E, Fraser AG, Merriman TR, Vishnu P, Krissansen GW. Polymorphisms in NFKBIA and ICAM-1
genes in New Zealand Caucasian Crohn's disease patients. J Gastroenterol Hepatol 2007; 22: 1666-1670.
70. MORGAN, A.R., HAN, D.Y.,
TRIGGS, C.M., LAM, W.J., FRASER, A.G., BARCLAY, M.,
GEARRY, R., FERGUSON, L.R. 'Genetic variation in the
matrix metalloproteinases is associated with inflammatory bowel disease', IPODD
annual meeting, Prague, 15-18 July, 2009
71. HAN, D.Y., FRASER, A.G.,
GRAINGER, P.A., FERGUSON, L.R. 'Environmental factors in
the development of chronic inflammation: A case-control study on risk factors
for Crohn,s disease within New Zealand', Mutation Research-Fundamental and
Molecular Mechanisms of Mutagenesis, Sep 12, p-, 2009,
doi:10.1016/j.mrfmmm.2009.09.002
72. HONG, J., LEUNG, E.,
FRASER, A.G., MERRIMAN, T.R., VISHNU, P., KRISSANSEN,
G.W. 'IL4, IL10, IL16, and TNF polymorphisms in New Zealand
Caucasian Crohn's disease patients.', International Journal of Colorectal
Disease, 23, (3), p335-337, 2008
Reviews, book chapters
1.
Fraser AG. Antiulcer drugs. New Ethicals February 1992
(revised and reprinted March 1994)
2.
Pounder RE, Fraser
AG. Duodenal ulceration. Recent advances in Gastroenterolgy . 9th edition 1992,
pp105-118.
3.
Fraser AG.
Gastro-oesophageal reflux and laryngeal symptoms. Aliment Pharmacol Therap 1994; 8: 265-272.
4.
Pounder
RE, Fraser AG. Peptic ulceration.
Diagnosis, medical management and complications. In Bockus Gastroenterology. Ed. Haubrick,
Schaffner, Berk, 5th edition 1994 pp
749-790.
5.
Pounder
RE, Fraser AG. Gastric acid
secretion: measurement in health and disease. Balliere's Clinical Gastroenterology, March 1993, Vol 7, No 1, pp 55-80.
6.
Richards
J, Charlesworth P, Fraser A. Therapeutic Forum - Reflux oesophagitis. Patient
Management April 1994 (reprinted
1997).
7.
Fraser AG, Rose T.
Nausea and vomiting. Patient Management, November 1994
(reprinted 1997).
8.
Rose T, Fraser AG. Dysphagia.
Patient Management, February1995.
9.
Rose
T, Fraser AG. Hepatitis A to E. Patient
Management, October1995
10.
Fraser AG. Dyspepsia.
Patient Management, December 1995 .
11.
Rose
T, Fraser AG. Chronic diarrhoea. - a clinical
approach. Patient Management Dec 1996
12.
Fraser AG. Editorial.
How helpful are tests for Helicobacter
pylori in general practice. New Ethicals Feb1997, pp 9-16.
13.
Fraser AG. Review.
The effect of alcohol on the pharmacokinetics of drug therapy. Clin
Pharmacokinetics 1997; 33: 79-90.
14.
Fraser AG. Is there an interaction between H2-antagonists
and alcohol? Drug Metabolism and Drug
Interactions 1998; 14: 123-146.
15.
Fraser AG. Microscopic colitis. Medicine International 2003; 31(2): 82-3.
16.
Fraser AG. Interpretation of liver enzyme tests: a
rapid guide. NZ Family Physician 2002;
29 (2): 117-120.
17.
Fraser AG. Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol
18.
Fraser AG. Inflammatory
bowel disease. NZ Family Physician.
2003; 30: 425-30.
19. Fraser
AG. Coeliac disease. NZ Family Physician 2004; 31:161-64
20. Fraser
AG. Fatty liver. NZ Family Physician 2004; 31: 399-401